Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection

NCT04361812 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Company R\&D Strategy Adjustment

Conditions

Similarity of Pharmacokinetics and Safety

Interventions

DRUG: HS632
DRUG: Omalizumab (Xolair®)

Sponsor

BioRay Pharmaceutical Co., Ltd.